Literature DB >> 33038958

Study of critically ill patients with COVID-19 in New York City.

Daniele Piovani1, Stefanos Bonovas2.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 33038958      PMCID: PMC7544488          DOI: 10.1016/S0140-6736(20)32072-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
Cummings and colleagues reported the epidemiology, clinical course, and outcomes of 257 critically ill adults with laboratory-confirmed COVID-19 admitted to two hospitals in New York City. The primary outcome was the rate of in-hospital death, and each patient had at least 28 days of observation. The authors report that, as of April 28, 2020, 101 (39%) of 257 patients had died, 94 (37%) remained hospitalised, four (2%) were transferred to another hospital, and 58 (23%) were discharged alive. Surprisingly, the authors show in figure 1 of their Article a cumulative incidence of in-hospital death of approximately 45% at 28 days. Given the numbers of patients at risk reported below the figure, we have identified that this result is not correct. Apparently, the authors censored the patients discharged alive (n=58) at the day of discharge. This methodological error has led to overestimation of the cumulative incidence of death, and distorted the results of the Cox proportional hazards regression. A fundamental assumption in survival analysis is that censoring should be non-informative—ie, that patients censored have the same survival prospects as those who continue to be followed up. Patients discharged alive should not have been censored; their status should be considered as event-free (ie, alive) throughout the study observation period. This methodological error in the COVID-19 literature is common yet serious. We kindly ask the authors to reanalyse the data, and correctly report the cumulative incidence, and the risk factors of in-hospital mortality, considering the above aspects.
  3 in total

Review 1.  Survival probabilities (the Kaplan-Meier method).

Authors:  J M Bland; D G Altman
Journal:  BMJ       Date:  1998-12-05

2.  Compassionate Use of Remdesivir in Covid-19.

Authors:  Stefanos Bonovas; Daniele Piovani
Journal:  N Engl J Med       Date:  2020-05-15       Impact factor: 91.245

3.  Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study.

Authors:  Matthew J Cummings; Matthew R Baldwin; Darryl Abrams; Samuel D Jacobson; Benjamin J Meyer; Elizabeth M Balough; Justin G Aaron; Jan Claassen; LeRoy E Rabbani; Jonathan Hastie; Beth R Hochman; John Salazar-Schicchi; Natalie H Yip; Daniel Brodie; Max R O'Donnell
Journal:  Lancet       Date:  2020-05-19       Impact factor: 79.321

  3 in total
  1 in total

1.  Prioritization of ICU beds with renal replacement therapy support by court order and mortality in a Brazilian metropolitan area.

Authors:  Ana Cristina Dos Santos; Simone Luzia Fidelis de Oliveira; Virgílio Luiz Marques de Macedo; Paula Lauane Araujo; Francine Salapata Fraiberg; Nélliton Fernandes Bastos; Richard Lucas Alves; Carlos Darwin Gomes da Silveira; Sérgio Eduardo Soares Fernandes; Francisco de Assis Rocha Neves; Fábio Ferreira Amorim
Journal:  Sci Rep       Date:  2022-03-03       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.